Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KMT2D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KMT2D (SET Domain) Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View KMT2D Products |
| Gene Delivery | KMT2D Promise-ORF / Lentivirus Full-length/Truncated ORF for stable cell line construction. |
View KMT2D Products |
| Benchmark Ab | Anti-KMT2D Recombinant Antibody Recombinant positive control for validation assays. |
View KMT2D Products |
| Validator | KMT2D siRNA Set For target knockdown and specificity verification. |
View KMT2D Products |
| Related Target A | WDR5 Core COMPASS complex component interacting directly with KMT2D; critical for PPI inhibitor assays. |
View WDR5 Products |
| Related Target B | KMT2A Key homolog target used for selectivity and off-target screening panels. |
View KMT2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large Molecular Weight (590 kDa) Target Expression | Highly stable, active SET domain catalytic fragments recombinantly expressed with verified sequence. |
| Homolog/Subfamily Selectivity Screening | KMT family profiling panel (KMT2A, KMT2C, KMT2D) available with >95% purity. |
| Lack of Assay Controls | Sequence-verified clinical benchmark antibodies and validated siRNA sets included. |
| Assay Inconsistency / Batch Variation | Strictly controlled endotoxin levels (<1 EU/µg) and SDS-PAGE purity verification. |
Live KMT2D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KMT2D therapeutics is intensifying, with major players shifting focus from traditional epigenetic modulators to specific protein-protein interaction (PPI) inhibitors and catalytic SET domain inhibitors. As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting synthetic lethal interactions and combination therapies in hematological malignancies and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI | Epigenetic Biotech, Academic Consortia | Lymphomas (DLBCL, FL), Breast Cancer | WDR5-KMT2D interaction disruption assays (Need high-purity recombinant complex proteins) |
| SET Domain Inhibitors | Global Pharmaceutical Corporates | Solid Tumors (ER+ Breast, Prostate) | Methyltransferase activity assays (Need highly active WT and mutant SET domain proteins) |
| PROTACs / Degraders | Targeted Protein Degradation Biotechs | Hematological Malignancies | Targeted degradation kinetics & selectivity assays (Need stable cell lines via Lentivirus) |